Pinnacle Biologics appoints two executives

Bannockburn-based Pinnacle Biologics, Inc.’s board of directors has elected Robert S. Altman as chief commercial officer and Sharon Ayd as chief scientific officer.

Altman is a proven leader with over 20 years experience in pharmaceutical industry, the company said in a release. He was most recently CEO and President of Marathon Pharmaceuticals, LLC. From 2004 to 2007 Bob served as Senior Vice President Marketing and Sales of Astellas Pharma U.S.  Previously, Altman worked at Abbott Laboratories for 16 years in a variety of positions, rising to vice president, general manager.

Altman received his bachelor of science in chemistry from the University of California, Riverside, his Ph.D. in Physical Chemistry from Harvard University, and his MBA from the University of Chicago, Booth School of Business.

Ayd has recently been consulting with Pinnacle leading the regulatory, quality and scientific affairs team. She  has a breadth of  pharmaceutical experience in entrepreneurial minded organizations, the company said. Most recently, Ayd was Vice President, Global R&D operations for the One 2 One business unit at Hospira Inc.  Previously she held a number of operating and senior management positions at startup biopharmaceutical companies.

Sharon received her bachelor of science in chemistry and biology at Northeastern Illinois University, her MBA at Lewis University and her Ph.D. in Biopharmaceutical Sciences at University of Illinois, Chicago.

“We are delighted to have Bob and Sharon join our team at Pinnacle Biologics”, said  Guillermo Herrera, executive chairman and CEO of Pinnacle.  “Bob is a proven individual who brings excellent experience at driving commercial performance. Sharon brings proven experience and discipline in delivering value in organizations progressing in clinical trials and expanding indications.“